U.S. Venture Partners (USVP) Research
Investment Thesis
U.S. Venture Partners (USVP) is a Menlo Park, California-based early-stage venture capital firm with four decades of investing history. The firm's stated mission is "partnering with entrepreneurs to transform their ideas into world-changing companies." USVP positions itself as a hands-on partner rather than a passive check-writer: its General Partners are former entrepreneurs, technologists, corporate executives, and financial professionals who typically take board seats and provide strategic counsel on scaling, team building, product development, and business development. The firm concentrates on four core sectors: cybersecurity, enterprise/cloud software, consumer (including e-commerce), and healthcare (medical devices, biotech/therapeutics, and IT-enabled healthcare services). USVP was ranked #55 in the Strebulaev-Jackson 2026 Top 100 VC ranking and #38 in the Biotech category, reflecting a durable, multi-decade track record particularly strong in medtech and therapeutics.
Stage Focus
USVP is explicitly early-stage focused, with a strategy of leading Series A or Series B rounds. The firm will also make selective seed investments and has shown willingness to continue supporting portfolio companies through later growth rounds (e.g., Series C follow-ons), but its core entry point is Series A/B.
Check Size
Based on external research (Waveup, market profiles), USVP typically writes first checks ranging from roughly $1M at seed up to $20M when leading a Series B round. The firm's own site does not publish check-size figures directly.
Lead Tendency
USVP is a lead investor. External sources consistently describe the firm's strategy as "being the lead Series A or B investor," and its own portfolio news frequently shows USVP-backed rounds with USVP named among lead/co-lead investors (e.g., Cato Networks, Slang AI, Route 92 Medical).
Recent Activity
USVP remains active. Recent financings involving USVP portfolio companies (per the firm's own news page and external coverage):
- July 2026: Surgical Safety Technologies rebranded as Aimbient (ambient AI in procedural environments).
- June 2026: Quantifind raised a $200M growth investment from Summit Partners to advance AI-native risk intelligence.
- June 2026: Apono was acquired by 1Password (exit).
- June 2026: Maneva (AI for manufacturing) raised a $27M Series A.
- May 2026: Cagent Vascular secured $41M for its dual-modality IVL platform.
- April 2026: Iantrek obtained $30M in growth capital from Trinity Capital for glaucoma/ophthalmic surgery expansion.
- April 2026: Route 92 Medical raised $50M to support its growth strategy.
- February 2026: Slang AI closed a $36M Series B for restaurant AI communications.
- December 2025: Informed.IQ secured $63M from Invictus Growth Partners for AI-powered fraud prevention/loan verification.
- November 2025: Okami Medical announced $45M in financing alongside a new CEO appointment.
- November 2025: Apono raised a $34M Series B for privileged access management (prior to its 2026 acquisition by 1Password).
- September 2025: Sparrow Pharmaceuticals closed a $95M Series B for its Type 2 diabetes therapy.
- June 2025: Cato Networks raised $359M at a $4.8B+ valuation.
USVP's most recently disclosed fund is USVP XIII, which closed in December 2022 at $400M. Total assets under management across the firm's 14 funds exceed $4.1B, with over $1.1B distributed to LPs since 2020. No new fund announcement was found for 2025-2026, but the steady cadence of new portfolio financings (6+ new company investments in the trailing 12 months per third-party trackers) indicates USVP XIII/XIV capital is still actively deploying.
Portfolio Highlights
USVP has invested in over 500 companies across four decades, with 542 total portfolio companies and 98 IPOs to date, and roughly $4.7B in cumulative capital deployed. Marquee names span all four focus sectors:
- Enterprise/Cloud Software: Box, Guidewire Software, Yammer, Nuance Communications, HelloSign, Human Interest, ON24, Smartling, Zerto, Mellanox Technologies, SanDisk, Sun Microsystems, MaxLinear.
- Security: Check Point Software, Imperva, Blue Coat Systems, Trusteer, ThreatMetrix, Kenna Security, Arkose Labs, Zero Networks, Hunters, Cato Networks.
- Consumer: GoPro, HotelTonight, Trunk Club, Pluto TV, MeetMe, PlaceIQ, Dstillery.
- Healthcare/Medtech/Biotech: Inspire Medical Systems, Inari Medical, HeartFlow, Castlight Health, Omada Health, Carrot (Carrot Fertility), Luma Health, Sparrow Pharmaceuticals, Route 92 Medical.
Notable exits/M&A include Nanostim (acquired), Savings.com (acquired), and Apono (acquired by 1Password, June 2026).
Team
- Dafina Toncheva — General Partner (security/cybersecurity focus)
- Rick Lewis — General Partner
- Jacques Benkoski — General Partner (healthcare/biotech focus)
- Matt Garratt — General Partner
- Casey Tansey — General Partner
- Jon Root — General Partner
- Dale Holladay — Chief Financial Officer
- Irwin Federman — Senior Advisor
- Steve Krausz — Senior Advisor
- Phil Young — Senior Advisor
- Mike Maher — Senior Advisor
USVP's team page does not publish LinkedIn URLs or emails; the above titles and names are drawn directly from the firm's team page.
Decision Process
USVP operates as a traditional multi-GP partnership (six General Partners plus senior advisors), consistent with partnership decision-making rather than a solo-GP or formal investment-committee structure.
Founder Preferences
USVP emphasizes technical and domain-expert founders in its four core verticals, particularly in cybersecurity and healthcare/medtech, where the firm's GPs bring direct operating and clinical/technical backgrounds. The firm markets its "network of 500 companies and 5,000 executives" as a differentiator for founder support beyond capital.
Geographic Focus
USVP is headquartered in Menlo Park, California, and its stated investment geography spans the United States and Israel, consistent with the firm's long history of cybersecurity investing (several portfolio companies, e.g., Trusteer, Imperva, ThreatMetrix, have Israeli roots).